Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis

20250 citationsJournal Articlehybrid Open Access

Authors

Falk G. Bechara · University Hospitals of the Ruhr-University of Bochum

Tanja Tran · UCB Pharma (Belgium)

Sandeep Kiri

Romy Bley · UCB Pharma (Germany)

Kathrin Schlüter · UCB Pharma (Germany)

Claudia Grellmann · Ingenieurgesellschaft Auto und Verkehr (Germany)

S. N. Melnik · Ev. Diakonissenkrankenhaus Leipzig

Abstract

The majority of HS-related claims were attributable to medications, followed by inpatient treatment, underscoring the need for therapies that provide long-term effectiveness and tolerability.

Topics & Keywords

Hidradenitis Suppurativa and Treatments Acne and Rosacea Treatments and Effects Dermatological and COVID-19 studies

Publication Details

Published in: JDDG Journal der Deutschen Dermatologischen Gesellschaft

DOI: 10.1111/ddg.15901

Field-Weighted Citation Impact: 0.00

Command Palette

Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis

Authors

Abstract

Topics & Keywords

Publication Details